Molecular Biology

Rony Seger (University of Washington, Seattle): “Protein kinases were traditionally classified into two main subgroups: those that phosphorylate serine or threonine residues on their protein substrates and those that phosphorylate tyrosine residues. However, several protein kinases recently have been shown to phosphorylate both types of residues. Our paper was one of the firstto describe these 'dual-specificity kinases,' showing that the mitogen-activated protein (MAP) kinases, ERK1 and ER

Written byRony Seger
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Rony Seger (University of Washington, Seattle): “Protein kinases were traditionally classified into two main subgroups: those that phosphorylate serine or threonine residues on their protein substrates and those that phosphorylate tyrosine residues. However, several protein kinases recently have been shown to phosphorylate both types of residues. Our paper was one of the firstto describe these 'dual-specificity kinases,' showing that the mitogen-activated protein (MAP) kinases, ERK1 and ERK2, undergo autophosphorylation on both tyrosine and threonine residues. “Although the number of dual-specificity kinases is constantly growing, the physiological relevance of many of them is not well understood (R.A. Lindberg, et al., Trends In Biochemical Sciences, 17:114-9, 1992). Our finding—that the autophosphorylation of MAP kinases occurs on threonine and tyrosine residues as the in vivo regulatory phosphorylation (N.G. Anderson, et al., Nature, 343:651-3, 1990) and is accompanied by some autoactivation—led us to propose that this autophosphorylation might be involved in the MAP kinase ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies